SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Follin Cecilia)
 

Search: WFRF:(Follin Cecilia) > (2020-2023) > Key Device Attribut...

Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours

Jørgensen, Jens Otto Lunde (author)
Aarhus University Hospital
de Herder, Wouter W. (author)
Erasmus University Medical Center
Martin, Wendy A. (author)
King's College Hospital
show more...
Kolarova, Teodora (author)
International Neuroendocrine Cancer Alliance - INCA
Marks, Muriël (author)
World Alliance of Pituitary Organizations (WAPO)
Follin, Cecilia (author)
Lund University,Lunds universitet,Barns och familjers hälsa,Forskargrupper vid Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Endokrin,Sena effekter efter barncancerbehandling,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Child and Family Health,Lund University Research Groups,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Endocrine,Late effects after childhood cancer treatment,LUCC: Lund University Cancer Centre,Other Strong Research Environments
Geilvoet, Wanda (author)
Erasmus University Medical Center
Melmed, Shlomo (author)
Cedars-Sinai Medical Center
show less...
 (creator_code:org_t)
2023
2023
English 14 s.
In: Advances in Therapy. - 0741-238X. ; 40:10, s. 4675-4688
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee. Results: Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%). Conclusion: The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Samhällsfarmaci och klinisk farmaci (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Social and Clinical Pharmacy (hsv//eng)

Keyword

Acromegaly
NETs
Neuroendocrine tumours
Somatostatin receptor ligand
SRL

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view